NCT07413263

Brief Summary

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
29mo left

Started May 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
May 2026Dec 2028

First Submitted

Initial submission to the registry

November 27, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

February 17, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2028

Last Updated

February 18, 2026

Status Verified

November 1, 2025

Enrollment Period

1.7 years

First QC Date

November 27, 2025

Last Update Submit

February 14, 2026

Conditions

Chronic Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

  • Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

    Assessment of change in HbA1c levels in CML patients treated with TKIs.

    Baseline and 3, 6, 9, and 12 months

Secondary Outcomes (1)

  • Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

    Baseline and 3, 6, 9, and 12 months

Interventions

Tyrosine kinase Inhibitors (Imatinib & Nilotinib)DRUG

these drugs used in CML only

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

CML patients

You may qualify if:

  • CML patients free medical history

You may not qualify if:

  • diabetic

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022.

    PMID: 35983065BACKGROUND

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

Tyrosine Kinase InhibitorsImatinib Mesylatenilotinib

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsMyeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Protein Kinase InhibitorsEnzyme InhibitorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesBenzamidesAmidesOrganic ChemicalsBenzoatesAcids, CarbocyclicCarboxylic AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrimidines

Study Officials

  • Mona mohamed soliman, prof

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nancy Atef Abdou, doctor

CONTACT

01027607363nancyatef918@gamil.com

mai mostafa kamal, prof

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident Doctor of Internal Medicine

Study Record Dates

First Submitted

November 27, 2025

First Posted

February 17, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2028

Last Updated

February 18, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share